Alexion Pharmaceuticals, Inc.
(NASDAQ : ALXN)

( )
ALXN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.93%169.220.0%$1420.50m
AMGNAmgen, Inc. -0.59%254.211.3%$686.16m
NVAXNovavax, Inc. -1.69%223.5080.0%$644.47m
SNSSSunesis Pharmaceuticals, Inc. 0.00%8.000.7%$559.23m
ILMNIllumina, Inc. 0.00%399.003.5%$519.65m
GILDGilead Sciences, Inc. -0.06%66.831.0%$470.22m
REGNRegeneron Pharmaceuticals, Inc. -0.12%502.002.7%$458.19m
VRTXVertex Pharmaceuticals, Inc. 0.28%220.001.9%$389.68m
ALXNAlexion Pharmaceuticals, Inc. 0.56%164.602.0%$350.06m
BNTXBioNTech SE 0.14%151.750.0%$314.00m
BIIBBiogen, Inc. 0.00%270.311.7%$263.29m
EXASEXACT Sciences Corp. -1.99%127.4518.4%$182.48m
NBIXNeurocrine Biosciences, Inc. 0.79%97.344.9%$181.15m
CRSPCRISPR Therapeutics AG -0.09%118.450.6%$166.42m
SGENSeagen Inc. 0.00%145.505.8%$146.84m

Company Profile

Alexion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.